Clinical Trial Update: β2-agonist Versus Ipratropium Bromide Associated With β2-agonists in Chronic Obstructive Pulmonary Disease Exacerbation [Phase 3]

View source ↗

Summary

Phase 3 trial comparing a β2-agonist versus ipratropium bromide in COPD exacerbation completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• IPRATROPIUM BROMIDE (IPRATROPIUM BROMIDE)
• β2-agonist

Snippet

Sponsor: University of Monastir | Conditions: Acute Exacerbation of Chronic Obstructive Airways Disease | Phase 3 | Status: COMPLETED